Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
DEBRA Research is backing Swiss biotech Topadur Pharma to develop small-molecule therapies for dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder causing chronic wounds and progressive scarring. The program will test Topadur's lead compound TOP-N53 and other molecules from its DualTOP® platform in preclinical models targeting wound healing and fibrosis — two of DEB's most debilitating features. It's a meaningful step forward for a condition with very few treatment options.
DEBRA Research, a global non-profit focused on epidermolysis bullosa (EB), has announced an investment in Swiss biotech Topadur Pharma to fund a preclinical program for dystrophic EB (DEB) — one of the most severe forms of this rare genetic skin disease. DEB is caused by mutations in the COL7A1 gene that impair collagen VII, leading to fragile skin, chronic wounds, progressive fibrosis, and serious functional impairment.
The program will evaluate Topadur's lead compound, TOP-N53, alongside other molecules from its proprietary DualTOP® platform, which is designed to modulate complementary signaling pathways involved in tissue repair. Research will be conducted in collaboration with the Medical Center – University of Freiburg and EB Research Institute GmbH in Salzburg, Austria.
Key Takeaways:
Why it matters: DEB patients face a cycle of wounding, scarring, and fibrosis that current wound-care treatments can't fully address. This investment signals a push toward therapies that tackle the disease's underlying biology, not just its symptoms.
